Current Treatments in Dry Age-Related Macular Degeneration

Dr. Özge Sarıtaş, FEBO

Battalgazi State Hospital, Department of Ophthalmology, Malatya, Türkiye

ABSTRACT

Multifactorial mechanisms, mainly genetic and environmental factors, have been demonstrated in the patho- genesis of dry- type age-related macular degeneration (dAMD). Pathways such as oxidative stress and chron- ic inflammation, including complement activation, which are believed to be significant in pathogenesis, are targeted for newly developed therapies. Currently, many early-phase clinical trials have been concluded pos- itively, and many more are expected to be concluded in the near future. The current treatments for dry AMD will be reviewed in this chapter.

Keywords: Age-related macular degeneration (AMD); Complement inactivating agents; Retina; Geographic atrophy (GA); Neuroprotection

Referanslar

  1. Coleman HR, Chan CC, Ferris FL, 3rd, Chew EY. Age-related macular degeneration. Lancet. 2008; 372:1835-1845. [Crossref]  [PubMed]
  2. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet.2012; 379:1728-1738. [Crossref]  [PubMed]
  3. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The complement system and innate immunity. [Link]
  4. Desai D, Dugel PU. Complement cascade inhibition in geographic atrophy: a review. Eye.2022;36(2):294-302. [Crossref]  [PubMed]  [PMC]
  5. Apellis Pharmaceuticals, Inc. Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration.
  6. Apellis Pharmaceuticals, Inc. A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration.
  7. Wykoff CC, Rosenfeld PJ, Waheed NK, et al. Characterizing new-onset exudation in the Randomized Phase 2 FILLY trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology 2021; 128:1325-1336. [Crossref]  [PubMed]
  8. Steinle NC, Pearce I, Monés J, et al. Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan. Am J Ophthalmol 2021; 227:116-124. [Crossref]  [PubMed]
  9. Efficacy of intravitreal pegcetacoplan in geographic atrophy:24-month results from the phase 3 OAKS and DERBY trials. Accessed July 24, 2023 [Link]
  10. FDA, FDA drug documenters, 2023. Accessed April, 2023 [Link]
  11. Apellis Pharmaceuticals, Inc. An extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL- 2) in subjects with geographic atrophy secondary to AMD (GALE). ClinicalTrials.gov identifier: NCT04770545. Up- dated August 30, 2022
  12. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration. Ophthalmology. 2021; 128:576-586. [Crossref]  [PubMed]
  13. Lueck K, Wasmuth S, Williams J, et al. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye (Lond). 2011; 25:1074-1082. [Crossref]  [PubMed]  [PMC]
  14. Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function -Cerniauskas- 2020 - STEM CELLS Translational Medicine [Crossref]
  15. Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023; 402:1449-1458. [Crossref]  [PubMed]
  16. Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degenera- tion: 18-month findings from the GATHER1 trial.Eye. 2023; 37:3551-3557 [Crossref]  [PubMed]  [PMC]
  17. Desai D, Dugel PU. Complement cascade inhibition in geographic atrophy: a review. Eye (Lond). 2022; 36:294-302. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geo-graphic atrophy due to age-related macular degeneration. Ophthalmology. 2021; 128:576-586. [Crossref]
  18. IVERIC bio, Inc. A phase 3 safety and efficacy study of intravitreal administration of Zimura (complement C5 inhibitor). ClinicalTrials.gov identifier: NCT04435366. Updated September 28, 2022. [Link]
  19. Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy.Accessed August, 2023 [Link]
  20. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, Zhang K, Sadda S, Feuer W, Rosenfeld PJ. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the complete study. Ophthalmology. 2014; 121:693-701 [Crossref]  [PubMed]  [PMC]
  21. Alexion Pharmaceuticals. A Phase 2, Double-Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). [Link]
  22. Gange WS, Sisk RA, Besirli CG. Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated leber congenital amaurosis. Ophthalmol Retina. 2022;6(1):58-64 [Crossref]  [PubMed]  [PMC]
  23. Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi- Had H, Dang W, Lin C, Mitra D, Zhu D, Thomas BB, Hikita ST, Pennington BO, Johnson LW, Clegg DO, Hinton DR, Humayun MS. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med. 2018;10: eaao4097. [Crossref]  [PubMed]
  24. Weiss J. Bone marrow derived stem cell ophthalmology treatment study II. ClinicalTrials.gov identifier: NCT03011541. Updated August 3, 2022.
  25. Ellis S, Buchberger A, Holder J, Hughes J. GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2020; 61:2295. [Link]
  26. Cashman SM, Gracias J, Adhi M, Kumar-Singh R. Adeno- virus-mediated delivery of factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for age-related macular degeneration. J Gene Med. 2015; 17:229-243. [Crossref]  [PubMed]
  27. Guymer RH, Wu Z, Hodgson LAB, Laser Intervention in Early Stages of Age-Related Macular Degeneration Study Group et al. Subthreshold nano-second laser intervention in age-related macular degeneration: the lead randomized controlled clinical trial. Ophthalmology. 2019; 126:829-838. [Crossref]  [PubMed]
  28. Markowitz SN, Devenyi RG, Munk MR, Croissant CL, Ted- ford SE, Rückert R, Walker MG, Patino BE, Chen L, Nido M, Tedford CE. A double-masked, randomized, sham-con- trolled, single-center study with photobiomodulation for the treatment of dry age related macular degeneration. Retina. 2020; 40:1471-1482. [Crossref]  [PubMed]  [PMC]
  29. Allegro Ophthalmics LLC. A Randomized Controlled, Double Masked, Crossover Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy Of 1.0 Mg Luminate®(Alg-1001) As A Treatment for Non-Exudative Macular Degeneration.
  30. Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014; 132:142-149. [Crossref]
  31. Saad L. A Phase 2/3 Multicenter, Randomized, Double masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
  32. GlobeNewswire. Galimedix therapeutics presents data showing safety, tolerability and potential for efficacy of its investigational eyedrops containing GAL-101 at glaucoma 360 conference, 2019
  33. Stealth Bio Therapeutics. Stealth biotherapeutics announces positive results for elamipretide in ophthalmic conditions, 2019. [Link]
  34. Pixium Vision SA. Feasibility Study of Compensation for Blindness with the PRIMA System in Patients with Dry Age-Related Macular Degeneration.
  35. Hudson HL, Lane SS, Heier JS, et al. Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology. 2006;113: 1987-2001. [Crossref]  [PubMed]
  36. Lylyk I, Bleise C, Lylyk PN, et al. Ophthalmic artery angioplasty for age-related macular degeneration. J Neurointerv Surg.2022; 14:968-972. [Crossref]  [PubMed]  [PMC]